DOSE INTENSIFICATION BY THE SIMULTANEOUS USE OF RHG-CSF AND ANTICANCER CHEMOTHERAPY

We have studied the simultaneous administration of rhG-CSF with doxoru bicin, the latter given by continuous infusion either intra-arterially or intravenously, in a group of patients with various sarcomas. This has enabled us to substantially increase the dosage intensity of doxor ubicin with a marked decrease in both hematologic and oral toxicity. W hile the data concerning anti-tumor activity is preliminary we believe that this combination has been responsible for a substantial increase in the effectiveness of doxorubicin in controlling the sarcomas. No a dverse effect from combining doxorubicin given by infusion with rhG-CS F has been noted to date.